Key Highlights
- Tempus AI launches Immune Profile Score (IPS) for clinicians to advance cancer care.
- Prognostic tool for stage IV pan-solid tumors undergoing immune checkpoint inhibitor (ICI) therapies.
- Validated in a study with 1,600 patients, IPS indicates survival benefits for “IPS-High” patients.
- Independent of traditional biomarkers like TMB, PD-L1, and MSI.
- Now available as an add-on to Tempus’ xT (DNA) and xR (RNA) assays.
Source: Business Wire
Notable Quotes
- “This study demonstrates that IPS scoring is beneficial in that it can identify patients, independent of standard biomarkers, who may have better overall survival with ICI therapy.” — Sandip Patel, MD, Professor at UC San Diego Health
- “We are excited to introduce this innovative test to clinicians, empowering them with the ability to make more informed choices for their patients.” — Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus
SoHC's Take
Tempus’ clinical launch of the Immune Profile Score (IPS) marks a significant advancement in precision oncology. By leveraging AI to develop a multimodal biomarker, Tempus equips oncologists with a novel tool that goes beyond traditional indicators, providing more nuanced prognostic data for patients with metastatic cancer. This innovative approach could potentially shift treatment paradigms, enabling more targeted immunotherapy applications. The study findings at the SITC Annual Meeting reinforce IPS’s unique prognostic value, offering substantial promise for improving survival rates and enhancing patient outcomes.
